It's also a thin line between positive confirmation bias and negative confirmation bias. Just as the pendulum swung too far to the upside, it has in my opinion swung too far to the downside, as evidenced by much of what we get on the thread.
"Maverick thinking is necessary to survive especially in times of crisis, when the rules of engagement in business change and when you set big goals to achieve big things."
http://www.ecademy.com/node.php?id=141844
Something to think about when speculating on what may or may not have happened with Lovenox, and why we now have such a diverse product portfolio targetted at satisfying the unmet needs of a much wider range of pharmaceutical customers.
Speaking of which, there's also some interesting reading to be found on nimble companies generally, and biotechs in particular. The story of J&J, once the dominant force in drug-eluting stents, is illuminating.
B&D can have the commoditised market. Long term, in the rapidly evolving medical devices market, Unilife has a far more attractive portfolio, and thus competitive advantage.
As always, time will tell, in the meantime all power to nimble mavericks.
For now the beach beckons. Hope you all had a great Australia Day.
UNS Price at posting:
37.5¢ Sentiment: Buy Disclosure: Held
